EntryPoint Capital’s Roivant Sciences ROIV Stock Holding History

EntryPoint Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$253K	Sell	7,144 -8,807	-55%	-$260K	0.06%	613
2026 Q1	$442K	Buy	+15,951	New	+$410K	0.13%	296
2025 Q4	–	Sell	-12,382	Closed	-$187K	–	833
2025 Q3	$187K	Buy	12,382 +963	+8%	+$11.9K	0.07%	563
2025 Q2	$129K	Sell	11,419 -34,661	-75%	-$376K	0.06%	546
2025 Q1	$465K	Sell	46,080 -7,363	-14%	-$79.6K	0.21%	122
2024 Q4	$632K	Buy	53,443 +40,964	+328%	+$484K	0.27%	43
2024 Q3	$144K	Buy	12,479 +11,331	+987%	+$129K	0.08%	519
2024 Q2	$12.1K	Buy	+1,148	New	+$12.6K	0.01%	1287
2024 Q1	–	Sell	-8,323	Closed	-$93.5K	–	1702
2023 Q4	$93.5K	Buy	+8,323	New	+$81.1K	0.09%	413

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

EntryPoint Capital's ROIV Position: Q2 2026 in Review

EntryPoint Capital reduced its Roivant Sciences (ROIV) stake by 55% in Q2 2026, selling an estimated $260K and leaving 7,144 shares worth $253K. The position accounts for 0.06% of the portfolio, ranked #613.

EntryPoint Capital first reported a position in ROIV in Q4 2023 and has held it in 9 quarters since. The position peaked at $632K in Q4 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

EntryPoint Capital held 7,144 shares of Roivant Sciences worth $253K as of Q2 2026.
EntryPoint Capital sold 8,807 Roivant Sciences shares in Q2 2026, an estimated $260K.
Roivant Sciences made up 0.06% of EntryPoint Capital's portfolio in Q2 2026, its #613 holding.
EntryPoint Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 9 quarters since.
EntryPoint Capital's Roivant Sciences position peaked at $632K in Q4 2024.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.